ImmuPharma plc

IMM.L · LSE
Analyze with AI
6/30/2025
3/31/2025
12/31/2024
9/30/2024
Operating Activities
Net Income-£919-£919-£1,048-£1,048
Dep. & Amort.£14£14£23£23
Deferred Tax£0£0£0£0
Stock-Based Comp.£28£28£28£28
Change in WC£49£49£148£148
Other Non-Cash-£175£326-£40£404
Operating Cash Flow-£503-£503-£446-£446
Investing Activities
PP&E Inv.£0£0-£1-£1
Net Acquisitions£0£0£0£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.£6£4-£189-£92
Investing Cash Flow£6£4-£190-£93
Financing Activities
Debt Repay.£0£0£0£0
Stock Issued£2,663£0£0£0
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.-£1,476£594£209£103
Financing Cash Flow£1,187£594£209£103
Forex Effect-£31-£15£24£12
Net Chg. in Cash£160£0-£848-£1,084
Supplemental Information
Beg. Cash£237£0£1,084£1,084
End Cash£397£0£237£0
Free Cash Flow-£503-£503-£447-£447